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PERSPECTIVES IN CLINICAL NEPHROLOGY
Hereditary and acquired cystic disease of the kidney
As a nephrologist thinks about the renal cystic diseases, several
observations emerge: first, the disorders are numerous and vari-
able in etiology; second, they span a wide range of both age of
presentation and severity of the renal disease; third, many of them
are systemic disorders; fourth, despite diverse etiologies, many of
them share similar processes of cyst formation. Additionally, one
cannot help but be impressed with the new information which has
emerged about the genetics, pathogenesis, clinical presentation
and management of these disorders in the last decade.
Renal cystic diseases have been classified in a variety of ways,
but from a clinical perspective it is perhaps most useful to
separate them into genetic and non-genetic (Table 1) disorders
since this approach guides evaluation and management. It is
worth remembering that not all genetic disorders are congenital
(onset at birth), and conversely not all congenital disorders are
heritable. Many of the congenital renal cystic disorders are part of
recognized syndromes, including chromosomal aberrations, such
as trisomy 9 and 18, and other rare autosomal recessive or
X-linked syndromes such as oro-facio-digital syndrome type 1;
these as well as congenital multicystic kidneys are reviewed in
detail elsewhere and are not discussed here [1, 2]. The genetic
disorders display both autosomal dominant and autosomal reces-
sive inheritance; the former include the most common genetic
disease in this country, autosomal dominant polycystic kidney
disease (ADPKD), while the recessive diseases are all uncommon.
The genetic diseases are often systemic disorders, perhaps reflect-
ing the fact that the protein abnormalities resulting from the gene
defects in these disorders likely influence the development and
function of more than one organ. Also in the genetic disorders,
the availability of gene linkage techniques have permitted identi-
fication of the chromosomes which carry the putative genes and in
some instances even the gene itself. This provided additional
diagnostic techniques (Fig. 1) and identified that some of the
disorders can actually be caused by different gene defects, such as
ADPKD which was thought to be a single entity, but can be
caused by defects on different chromosomes.
The non-genetic disorders encompass both developmental ab-
errancies and acquired disorders (Table 1), many of which are
common disorders.
The pathobiology of cystogenesis
The fact that renal cysts occur in so many disorders suggests
that there is not likely to be a single pathogenetic mechanism for
cystogenesis; rather, multiple heritable or acquired defects could
mediate cyst formation. Indeed, experimental data and clinical
observations suggest that there are at least three components of
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cystogenesis: cell proliferation, fluid secretion, and extracellular
matrix abnormalities.
Increased renal epithelial proliferation is manifested in multi-
ple ways in the cystic disorders. In ADPKD hyperplasia includes
polyps of the cyst-lining epithelium [3], microscopic renal adeno-
mas [4] and increased proliferation and responsiveness of cultured
ADPKD cyst epithelia to mitogens such as EGF [5]. Similarly, in
tuberous sclerosis (TS), renal cysts demonstrate hyperplastic
epithelia with nodular extensions into the lumen and angiomyo-
lipomas [6]. The renal cystic epithelia in Von-Hippel-Lindau
(VHL) disease display a histopathologic continuum from normal
to hyperplastic to malignant epithelia [7]. Moreover, in VHL and
TS the responsible genes are mutated tumor suppressor genes [8,
9], confirming the hypothesis that increased cell proliferation can
lead to cyst formation. This concept is supported by the observa-
tion that renal cysts occur in transgenic animal models in which
c-myc or HrasT24 is in the transgene [10, 11]. The question of an
interrelationship of such oncogenes with genes regulating cell
death has also been raised by recent experimental studies [12].
Increased cell proliferation alone would be expected to result
only in the solid tumors seen in these disorders. It is apparent that
fluid secretion is also necessary to form a fluid-filled cyst. Direct
evidence comes from in vitro studies of MDCK cells suspended in
collagen matrix [13]. In defined medium alone, these cells do not
proliferate or form cysts. If EGF is added, dense, solid balls of
cells form. If a cAMP-agonist is added, which stimulates both cell
proliferation and fluid secretion, cysts are formed [13]. This fluid
secretion by cyst epithelia is demonstrated by studies on intact
cysts excised from human ADPKD kidneys which vigorously
secrete fluid when they remain filled with the original cyst fluid or
when stimulated with a cAMP agonist [14]. The secretory and
cystogenic capacity of ADPKD cyst fluid is also demonstrated
both by its ability to stimulate fluid secretion by monolayers of
MDCK and human kidney cortex cells in cell culture and to
induce cyst formation in both these cell types in collagen matrix
[13].
Clinically this secretory capacity of cyst epithelia is seen when
cysts are punctured and drained; they will rapidly reaccumulate
fluid if the epithelium is not altered with alcohol sclerosis [15, 16].
The critical role of fluid secretion in cystogenesis offers a potential
for ultimate treatment of these disorders with agents which inhibit
epithelial fluid secretion.
Alterations of the extracellular matrix in the cystic disorders are
suggested by the splitting, duplication and lamination of tubular
basement membranes (BM) seen in early stages of ADPKD [17];
the thickened BM of cyst-lining epithelia at later stages of
ADPKD [18]; the thickened tubular BM in a drug-induced rat
model of PKD [19], and extremely thin, attenuated tubular BM
adjacent to thickened and laminated areas in patients with
juvenile medullary cystic disease [20]. In cell culture ADPKD
epithelia elaborate a grossly abnormal-appearing extracellular
matrix [18]. Some studies have shown reduced de novo synthesis of
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Table 1. Genetic and non-genetic renal cystic disorders
Genetic
Autosomal dominant
Autosomal-dominant polycystic kidney disease
Tuberous sclerosis
Von-Hippel-Lindau disease
Adult-onset form of medullary cystic disease
Autosomal recessive
Autosomal-recessive polycystic kidney disease
Juvenile nephronophthisis
Cysts associated with multiple malformation syndromes
Chromosome disorders
Autosomal recessive syndromes
X-linked syndromes
Non-genetic
Developmental disorders
Multicystic dysplasia
Medullary sponge kidney
Acquired disorders
Simple renal cysts
Multilocular cystic nephroma
Hypokalemic cystic disease
Acquired renal cystic kidney disease(in chronic renal failure patients)
proteoglycans by human ADPKD cyst-derived epithelia and an
altered composition of various proteoglycan fractions [21]. Fi-
nally, the array of systemic disorders present in a disease like
ADPKD is compatible with a matrix disorder.
One possible explanation for these alterations in proliferation,
secretion and matrix in cystic epithelia is that cyst epithelium is
either incompletely differentiated or partly dedifferentiated. In
hereditary or developmental disorders, a block in the normal
tubular development could lead to continued cell growth without
terminal differentiation, whereas an insult to mature kidneys
could cause dedifferentiation [22]. This concept is supported by
the observation of an immature phenotype of cyst-lining epithelia,
the abnormal expression of developmentally regulated genes in
cpk mice [23], the overexpression of differentiation antigens and
growth-related genes in human ADPKD cells [24], reduced distal
tubular EGF expression with consequent lack of collecting duct
maturation in cpk [25] and pcy mice [26], and persistence of fetal
proteins in human ADPKD and ARPKD epithelia [27, 28].
Abnormal responsiveness to growth factors [5, 18] and the
mislocation of Na-K-ATPase to apical plasma membranes ob-
served in human ADPKD kidneys [29] are compatible with an
immature state [27]. The presence of Na-K-ATPase on apical
membranes of collecting tubules has also been shown in develop-
ing cpk mice [30]. Likewise, the abnormal basement membrane
composition has been viewed as reflecting an undifferentiated
stage of renal tubules [21, 23].
The observation which is most intriguing for the clinician is the
reversibility of cystic lesions, This has been shown to occur in
drug-induced animal models with removal of the cystogene [31],
in bypokalemic-induced renal cysts with reversal of the hyperal-
dosterone state [32], and in acquired cystic disease with removal
of the uremic environment [33]. Thus, there might also be
potential for reversal of the other polycystic lesions once the
putative stimuli are identified in other disorders. Moreover,
availability of drugs which interfere with proliferation and secre-
tion could also impact disease progression.
Renal cystic disorders
Autosomal-dominant polycystic kidney disease
Epidemiology and genetics. ADPKD has a world-wide distribu-
tion and an estimated prevalence of 1:200 to 1:1000. ADPKD
demonstrates genetic heterogeneity with two and possibly three
causative genes. About 90% of white families of European origin
have the gene located on the short arm of chromosome 16
(ADPKD1) [34]. A second gene locus is on chromosome 4
(ADPKD2) [35, 36]. There is a recent preliminary report of a
family whose ADPKD gene is not linked to either chromosome 16
or 4, suggesting yet a third gene [37]. Recently, the ADPKD1 gene
has been identified; but the function of the protein has not been
determined (note added in proof, A).
There are phenotypic differences between ADPKD1 and AD-
PKD2, with ADPKD2 individuals developing hypertension and
ESRD at an older age than ADPKD1 individuals (mean age at
ESRD 69.4 1.7 vs. 56.7 1.9 years) [38]. However, even within
ADPKD1 families there is considerable variability both in the
occurrence of extrarenal manifestations and in the severity of the
renal disease [39, 40]. For example, within a family, some mem-
bers may reach ESRD more than 30 years earlier than others [40].
In addition, some families have one or more offspring who are
diagnosed in utero or in the first year of life from a mother with
typical adult onset disease [41]. This phenotypic variability within
families has both clinical and scientific implications. Clinically it
means that when counselling ADPKD families one cannot assume
the disease will have a similar course in a given family. From a
more scientific perspective, this variability is of interest because of
its similarities with diseases such as fragile-X syndrome, myotonic
dystrophy, and Huntington's disease [42—44]. The underlying
molecular mechanism in these diseases is unstable DNA, with
varying numbers of triplet repeats within the gene in different
family members relating to different age of onset and disease
severity [45—47]. Whether a similar mechanism is operative in
ADPKD or whether this intrafamilial variability is due to the
interaction of the ADPKD genes with other modifying genes or
environmental factors is not yet clear. However, the identification
of the ADPKD1 gene will permit this question to be answered in
ADPKD1 families. The unstable DNA would also explain the
apparent high spontaneous mutation rate and the variability in
extrarenal manifestations. This question of etiology of phenotypic
variability is of interest not only in ADPKD but also in the other
systemic renal cystic diseases, particularly TS, which shows many
of the same features of differing age of onset, variable phenotypic
expression and severity of disease.
Diagnosis, clinical manifestations, and management consider-
ations. The mainstay for diagnosing ADPKD is ultrasonography.
Its only limitation is that it relies on the presence of renal cysts to
define the gene carrier state. In ADPKD1 families 64% of
affected children under the age of 10 years and about 90% of
teenagers between 10 and 19 years who are presumed gene
carriers have detectable renal cysts [48]. The reliability of ultra-
sonography for ADPKD2 patients has not yet been defined, Gene
linkage analysis can be used to determine the status of an at-risk
individual who does not yet have detectable renal cysts. Even with
the cloning of the ADPKD1 gene, gene linkage analysis remains
the only method available in ADPKD2 families and may still need
to be used in ADPKD1 families until specific gene testing is
commercially available. An example of an application for this
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Table 2. Frequency of renal manifestations of autosomal-dominant
polycystic kidney disease in adults
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Manifestation Frequency
Anatomical
Renal cysts 100%
Renal adenomas 21%
Cyst calcification Common
Functional
Decreased renal concentrating Affects potentially all adults
ability
Decreased urinary citrate 67% (10/15 subjects)
excretion
Impaired renal acidification Unknown
Hormonal alterations
Increased renin production Probably affects all hypertensive
adults
Preserved erythropoietin Probably affects all ESRD
production patients
Complications
Hypertension Affects 60—75% of adults
Hematuria and/or hemorrhage 50%
Acute and chronic pain 60%
Urinary tract infection: Common
bladder, interstitium, cysts
Nephrolithiasis 20%
Nephromegaly 100% of adults
Renal failure Affects 50% of patients by age
60
Ill
Fig. 1. Pedigree of a kindred with ADPKD1. Circles denote female family
members, squares male family members, and solid symbols affected
members. Ages are shown in parentheses. Subject Ill-i wished to know
her status before her marriage. Ultrasonography was negative. Two types
of chromosome l6p markers were used (C and D). The three possible
alleles are indicated (1, 2 and 3). Markers C and D are assumed to flank
the ADPKD1 gene locus. These types are depicted below each symbol. In
this family the haplotype C3, D2 is transmitted with the ADPKD1 gene.
Therefore, Subject Ill-i has an approximately 99% chance of being a gene
carrier. This type of linkage analysis can be performed in hereditary
disorders for which the chromosome location of the gene has been
determined. (With permission of GABOW PA: Autosomal dominant
polycystic kidney disease. N Engi J Med 329:332—342, 1993)
technique is shown in Figure 1. An 18-year-old woman who had
no cysts by ultrasonography had approximately a 10% chance of
carrying the gene (if she was in an ADPKD1 family). She wished
a more precise answer regarding her gene status. This could only
be obtained with gene linkage; this could be performed in her
because she had 2 other affected family members which were
necessary to identify the marker haplotype travelling with the
ADPKD gene in this family.
Before performing gene linkage or before any screening is
done, patients must be competently informed about the potential
psychological and insurance implications of a positive diagnosis.
These are issues of particular concern in screening children [49].
Because of the expense of gene linkage techniques, the need to
involve other family members and the reliability of ultrasonogra-
phy, gene linkage will likely be limited to circumstances in which
family planning would be altered, or for potential kidney donors
when ultrasound findings are nondiagnostic [49, 50]. Although the
need to involve other family members will not be required
eventually for the ADPKD1 gene, the other advantages of ultra-
sonography will still remain.
ADPKD is a systemic disease with both renal and extrarenal
manifestations (Tables 2 and 3). The anatomic renal manifesta-
tion is diffuse renal cystic disease; the cysts are distributed
throughout the cortex and medulla (Fig. 2). The common clinical
renal manifestations are chronic flank and/or back pain, hematu-
na, infection, nephrolithiasis and hypertension [51]. Pain, hema-
tuna and hypertension occur more often in patients with larger
kidneys [52—54]. The relationship between renal and/or cyst size
and pain is demonstrated by the long-term relief achieved in
patients with disabling pain who undergo cyst decompression [55,
56].
Adapted from GABOW PA: Autosomal dominant polycystic kidney
disease. N Engi J Med 329:332—342, 1993. Used with permission.
Both microscopic and gross hematuria occur in ADPKD; acute
episodes of macroscopic hematuria can be caused by cyst hemor-
rhage, infection or nephrolithiasis. Cyst hemorrhages are best
managed conservatively, with bed rest and mild analgesics [57]. If
a particular activity reproducibly provokes hematuria, this activity
should be discouraged since repeated episodes of gross hematuria
have been associated with decreased renal function [53].
Nephrolithiasis occurs in 20 to 36% of ADPKD patients [58,
59]. This high frequency may be related to both urinary stasis
secondary to cyst compression of tubules and metabolic factors
such as hypocitraturia, hyperoxaluria and hyperuricemia which
have been found to occur in ADPKD patients with nephrolithiasis
and normal renal function [58].
Infection can occur as lower urinary tract infection, renal
interstitial infection (pyelonephritis), renal cyst infection or pen-
nephric abscess. Although lower UTI and pyelonephritis are
managed as in the general population, renal cyst infection re-
quires the administration of lipid-soluble antibiotics such as
trimethoprim-sulfamethoxazole, chloramphenicol or ciprofloxa-
cm which can penetrate cyst walls [57].
Hypertension is an early and common manifestation of
ADPKD. Sixteen percent of children under the age of 18 years
have blood pressures above the 95th percentile for age- and
gender-matched children [601 and 60 to 75% of adults are
hypertensive before impairment of renal function [51]. Moreover,
in one study ADPKD adults between 15 and 25 years of age had
significantly elevated left ventricular mass compared to controls,
attesting to the biologic significance of the blood pressure eleva-
tion early in the course of the disease [611. Numerous studies have
shown that the renin-angiotensin system is activated in patients
with ADPKD [62—66], presumably via disruption of the renal
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Table 3. Extrarenal manifestations of the hereditary cystic diseases
Autosomal-dominant polycystic kidney disease
Gastrointestinal
Hepatic cysts
Congenital hepatic fibrosis (rare)
Pancreatic cysts (uncommon)
Diverticuli
Cardiovascular
Cardiac valve abnormalities
Intracranial aneurysms
Musculoskeletal
Hernias
Extrarenal cysts
Ovaries
Testicles (rare)
Arachnoid
Spleen
Tuberous sclerosis
Skin
Adenoma sebaceum
Hypomelanotic maeules
Ungual fibroma
Central nervous system
Cortical tubers
Glial nodules
Giant cell and retinal astrocytomas
Cardiovascular
Rhabdomyomas
Gastrointestinal
Hepatic angiolipoma
Pulmonary
Malignant lymphangiomyomatosis
Von-Hippel-Landau disease
Central nervous system
Brain hemangioblastoma
Retinal angiomas
Spinal hemangioblastomas
Endocrine
Pheochromocytoma
Pancreatic islet cell tumors
Miscellaneous cysts
Pancreatic
Epididymal
Autosomal-reeessive polyeystic kidney disease
Gastrointestinal
Congenital hepatic fibrosis
Juvenile nephronophthisis
Gastrointestinal
Congenital hepatic fibrosis
Ocular
Tapetoretinal degeneration
Bone
Cone shaped epiphyses
vasculature by cysts and the subsequent development of intrarenal
ischemia.
ESRD does not occur in every ADPKD patient. In fact, several
studies have shown that by age 60 only about 50% of patients have
reached ESRD [67, 68]. Factors which have been reported to
contribute to a faster rate of progression are the ADPKD1
genotype, male gender, younger age at diagnosis, hypertension,
increased left ventricular mass, hepatic cysts in women, three or
more pregnancies, multiple episodes of gross hematuria, urinary
tract infections in men, and increased renal volume [38, 52, 68,
691. Some of these factors such as hypertension, infection and
pregnancies are amenable to intervention and their modification
may improve the renal outcome of ADPKD patients. Once ESRD
has been reached, ADPKD patients are good candidates for
hemo- or peritoneal dialysis and renal transplantation [70].
The most common extrarenal manifestation is hepatie cysts
which are rarely seen in children but increase with age, declining
renal function, and parity in women. Seventy-seven percent of
patients over the age of 60 have hepatic cysts [71]. Massive hepatic
cystic disease occurs predominantly in women [72, 73]. This
observation and the relationship of disease severity to parity
suggest a pathogenetic role for female steroid hormones in
hepatic cystogenesis [72]. Liver function is normal unless a
complication such as infection or malignancy is present [73, 74].
For the rare patient with a grossly enlarged liver and disabling
pain, surgical resection and decompression is a therapeutic option
[75]. Although congenital hepatic fibrosis is generally associated
with ARPKD, some cases have been described in association with
ADPKD [76—78], and even Caroli's disease coexisting with con-
genital hepatic fibrosis and polycystic liver and kidney disease in
the same patient has been reported [79].
The other common gastrointestinal tract manifestation is co-
Ionic diverticula and associated complications which occur more
often in ADPKD-ESRD patients compared to ESRD patients
with other diseases and to the general population [51, 80]. Hernias
also occur more often than in the general population [51]. The
most devastating extrarenal manifestation is a ruptured intracra-
nial aneurysm (ICA). Three recent prospective studies have
shown a frequency of ICA in asymptomatic ADPKD patients
between 5 and 11% [81—83]. There may be family clustering of
ruptured ICA [83—86], and rupture of an ICA in ADPKD seems
to occur at a younger age and with smaller aneurysms than in the
general population [82, 83, 87]. Screening for ICA by noninvasive
methods such as dynamic CT or magnetic resonance angiography
currently is recommended only for patients with a family history of
ruptured ICA, patients with a previous ruptured ICA, those
engaged in an activity where loss of consciousness would place
them or others at extreme risk, or those who are undergoing a
surgical intervention likely to be associated with hemodynamic
instability with hypertension [87—90], A flow chart of our current
recommendations is displayed in Figure 3.
Cardiac valvular abnormalities are also common in ADPKD.
Mitral valve prolapse has been shown in two prospective echocar-
diographic studies to occur in about 25% of ADPKD patients,
compared to only 2% of controls [91, 92]. This is often associated
with atypical chest pain or palpitations [91, 92]. The natural
history of these cardiac valvular lesions is uncertain, but some
ADPKD patients have required valve replacements [93]. In
general, an assessment for extrarenal manifestations should occur
only when clinically indicated.
Tuberous sclerosis
Epidemiology and genetics. Tuberous sclerosis (TS) is character-
ized by multiple hamartomas, which are benign congenital tumors
composed of abnormally arranged and differentiated tissues in
brain, retina, skin, heart, kidneys, liver, lung and bone. It is much
more common than previously thought with recent prevalence
estimates of 1:5800 to 1:10000 [94—96]. Inheritance is autosomal
dominant with genetic heterogeneity. Linkage to chromosome 9
has been established for about one-third of families [97]; linkage
has also been reported to markers on chromosomes 11, 12 and 16
[98—100], but recent evidence has questioned the existence of TS
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Fig. 2. (A) ADPKD kidney with visible cysts on the kidney's surface. (B) Cut
section of the ADPKD kidney showing cortical and medullary cysts of
varying size.
genes on chromosomes 11 and 12 [9]. In most, if not all multi-
generation families the disease appears to be caused by a muta-
tion either on chromosome 9 or 16 [9]. Recently the TS gene
located on chromosome 16 (TSC2) has been identified, and
interestingly lies in the same region as the ADPKD1gene [9]. The
protein product, tuberin, has homology with proteins involved in
cell proliferation and differentation [9].
About two-thirds of cases seem to be new mutations in that they
have a negative family history [94, 95, 99, 101], but as in ADPKD,
a negative family history could reflect minimal disease in parents
who remain undiagnosed rather than a true new mutation. TS is
characterized by extreme variability of phenotypic expression,
with some members of a family having fatal disease complications
and others being normal on routine clinical examination [101,
102].
Diagnosis, clinical manifestations and management consider-
ations. The diagnosis of TS is usually made by a typical constel-
lation of clinical findings [95, 103]. These include skin lesions such
as facial angiofibromas (adenoma sebaceum), hypomelanotic
macules, and ungual fibromas. Central nervous system manifesta-
tions, some of which are considered pathognomonic and are best
diagnosed by CT or MRI of the brain, include multiple cortical
tubers, subependymal glial nodules, giant cell astrocytoma, and
retinal astrocytomas [95]. Seizures can occur in up to 80% of
patients [94, 95, 102], and about 50—60% of patients are mentally
retarded [94, 95, 102]. The heart may be affected by benign
rhabdomyomas, the liver by angiomyolipomas, and the lung by
malignant lymphangiomyomatosis.
Renal manifestations occur in 50 to 100% of patients, most
often as multiple and bilateral angiomyolipoma, with or without
cysts, and rarely as renal cell carcinoma [6]. TS mimicking
ADPKD has repeatedly been described in adults and children
[104—107]. Tuberous sclerosis should be entertained as an alter-
native diagnosis in patients with presumed ADPKD when the
patient appears to be a spontaneous mutation, is older without
liver cysts, has radiologically detectable solid masses as well as
cysts, and of course when any pathognomonic findings of TS are
present. The cysts in TS have a unique lining with eosinophilic and
nodular hyperplastic epithelium [6]. Renal failure can result from
extensive involvement of both angiomyolipoma and cysts but is
more common with polycystic kidneys [6, 105]. In one study, renal
disease was the most common cause of death occurring in patients
older than 10 years and increased in frequency with advancing age
[108].
Management recommendations are to periodically monitor TS
patients with MRI of the brain, renal ultrasonography, renal
function studies, and chest X-ray, because most causes of death
result from potentially treatable causes [102]. In patients present-
ing predominantly as polycystic kidney disease, screening for
other clinical features of TS is important to verif' the diagnosis.
Von-Hippel-Lindau disease
Epidemiology and genetics. Von-Hippel-Lindau disease (VHL)
is a rare (about 1:36000 live births) autosomal dominant disease
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characterized by multiple tumors, most often retinal angiomas,
CNS and spinal haemangioblastomas, renal cell carcinomas and
pheochromocytomas. Cysts in kidneys, pancreas and epididymis
are also frequent findings [109]. Penetrance is more than 90% by
age 60 years [109]. Linkage of the VHL disease gene to markers
on the short arm of chromosome 3 was reported in 1988, and
subsequently linkage analysis was shown to accurately predict
gene carrier status in 88% of asymptotnatic members of disease
families [1101. There is no evidence for genetic heterogeneity
[110], and new mutations seem to be uncommon (less than 10%)
[109]. Recently, the VHL gene itself, a tumor suppressor gene,
was identified [8]. Interestingly, renal cell carcinoma cell lines
obtained from patients with sporadic renal cell carcinoma showed
mutations in the same tumor suppressor gene [8].
Diagnosis, clinical manifestations and management consider-
ations. The diagnosis in a family member is made when one or
more disease manifestations are present [110]. When there is no
family history, two or more hemangioblastomas or one heman-
gioblastoma and one visceral manifestation are required for
diagnosis [1091. The mean age at onset in one study was 26.3
years, with retinal angioma as the first manifestation in 43% of
patients, cerebellar hemangioblastoma in 39%, and renal cell
carcinoma in 10% [109]. Renal cysts occur in up to 76% of
patients and may be detected in the second decade, whereas renal
carcinomas usually occur at a mean age of 44 years [109]. Renal
cell carcinomas can be present in patients who also have cysts [7].
The carcinomas are often multiple and bilateral and occur at
younger ages than tumors in the general population. Renal
carcinoma was the leading cause of death in one study, accounting
for 47% of all deaths [109].
Some VHL families have a high incidence of pheochromocy-
toma. Conversely when unselected patients with pheochromocy-
toma were screened, 19% were found to be carriers of VHL [11 1],
Pancreatic and epididymal cysts appear to be common, although
their exact incidence is not known [109].
Gadolinium-enhanced MRI of the brain, ophthalmoscopy, and
CT of the abdomen are considered the best screening procedures
for family members who may be gene carriers [111, 112]. The
management of renal cystic disease is not clear because of the
possibility of coexisting carcinoma even in benign-appearing cysts.
Bilateral nephrectomy versus a conservative approach with regu-
lar screening and tumor enucleation have both been advocated.
Autosomal-recessive polycystic kidney disease
Epidemiology and genetics. ARPKD is a rare genetic disorder
with reported incidence from 1:6000 to 1:55,000 in various studies
[113, 114]. Given the autosomal recessive inheritance, the parents
are always unaffected and each offspring has a one in four chance
of inheriting the defective gene from each carrier parent and
hence the disease. A gene for ARPKD has been located on
chromosome 6 (note added in proof, B). Therefore, linkage
studies for diagnosis are now available. No genetic heterogeneity
was found in the first 16 families studied (note added in proof, B).
Since the disease can present from perinatal life to early adult-
hood, four distinct genetic entities had been proposed in the past,
based on the age at presentation: perinatal, neonatal, infantile and
juvenile [115]. However, the observation of different ages of
presentation in siblings from the same family led to the view that
there is one causative gene [116—118]. Linkage analysis in more
families will provide further information on this. All affected
children have both renal and hepatic abnormalities, but younger
children have a predominance of the renal disease and older
children and adolescents manifest more significant hepatic disease
[114, 117—119].
Diagnosis, clinical manifestations and management consider-
ations. The diagnosis is usually made by imaging studies of the
child. Characteristic ultrasonographic findings prenatally and in
young children are enlarged, hyperechoic kidneys with poor
differentiation between cortex and medulla. However, these signs
are not specific since they can also be seen prenatally or in infants
with ADPKD [114, 117, 120]. Older children with ARPKD can
develop macrocysts, and the appearance of the kidneys on US can
resemble ADPKD. Other less common entities can also have a
similar radiographic appearance to ADPKD [119]. The differen-
tiation between ARPKD and ADPKD depends heavily upon the
ultrasonographic findings in the parents. Providing non-paternity
has been excluded, the finding of a normal ultrasonogram in both
parents, particularly if they are over thirty years of age, supports
the diagnosis of ARPKD. When parents are not available for
study or have equivocal findings, biopsy of the patient's kidneys or
liver may be required to establish the diagnosis of ARPKD [119].
Although ultrasonographic similarities exist between ARPKD and
ADPKD, pathologically the disorders are distinct both in the
kidneys and the liver. The kidneys in ARPKD display numerous
small fusiform cysts, generally 1 to 8 mm in size, in the medulla
and cortex (Fig. 4). These cysts arise from dilated distal tubules
and collecting tubules and are aligned in a radial distribution (Fig.
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Fig. 4. (A) ARPKD kidney showing little distortion of the external surface.(B) Cut section of the ARPKD kidney demonstrating fusiform cysts with
a radial distribution.
4). The liver displays a varying severity of congenital hepatic
fibrosis with proliferation of bile ducts, periportal fibrosis, a
scarcity of portal vein branches and an absence of inflammatory
changes. Because congenital hepatic fibrosis is very rare in
ADPKD, these findings together with the specific renal histology
establish a diagnosis of ARPKD.
Although prenatal diagnosis by US has been possible as early as
the 14th week of gestation [121], often renal abnormalities
become apparent only in the third trimester [114, 121], and both
false negative and false positive prenatal ultrasound diagnoses
have been reported [121, 122], the latter particularly if there is no
prior family history [123]. Moreover, even severe prenatal abnor-
malities do not necessarily predict a fatal outcome [124]. For a
clinician it is most important to remember that not all renal cystic
disease presenting in utero, infancy or childhood is ARPKD.
Most patients present at birth or in early infancy, most com-
monly with abdominal masses due to the enlarged kidneys [114,
118, 1251. Some of these severely affected children still die in the
first month of life of respiratory failure due to pulmonary hyp-
oplasia [114, 118, 119]. Children who survive the neonatal period
often have adequate renal function for many years [118, 119, 126],
although they always have decreased urinary concentrating capac-
ity. Hypertension is common and often severe, requiring therapy
in early childhood [114, 118, 119, 126]. In older children and
adolescents signs of liver involvement with hepatosplenomegaly,
portal hypertension and bleeding esophageal varices predominate
over the renal disease; liver function tests, however, are always
normal [117, 119], unless cholangitis supervenes.
Management is directed at the renal and hepatic complications
and includes treatment of hypertension and urinary tract infec-
tions and renal replacement therapy with dialysis and transplan-
tation. The complications of portal hypertension may require
esophageal scierotherapy or portacaval shunting. With modern
treatment modalities the prognosis is not as grim as previously
reported. In one study the life-table survival rate was 46% at 15
years for all children and 79% at 15 years for those who had
survived the first year of life [125].
Juvenile nephronophthisis—Medullaiy cystic disease
Epidemiology and genetics. Two different terms, juvenile neph-
ronophthisis (JN) and medullary cystic disease (MCD), have been
used for diseases with similar renal morphology but different types
of inheritance, ages of onset, and associated abnormalities. Both
disorders are characterized by slowly progressive renal insuffi-
ciency with shrunken kidneys, and histologically by prominent,
diffuse interstitial lesions [127]. It is probable that different genes
are responsible for the two entities. JN shows an autosomal
recessive inheritance, presents in childhood, and progresses to
ESRD before the age of 25, whereas MCD shows an autosomal
dominant inheritance and presents later in life, up to the fourth or
fifth decade [127—129]. Recent linkage studies have mapped the
gene for JN to chromosome 2p, whereas linkage for Senior-Loken
syndrome, which is nephronophthisis with retinal degeneration,
was not linked to this site [130, 131]. Another phenotypic form has
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Table 4. Approach to a patient with renal cystic disease
Obtain family histoty including autopsy data
Construct pedigree
Determine if consanguinity is present
May need ultrasonography of parents
Careful physical examination
Blood pressure
Assessment for extrarenal manifestations
Skin, eyes, heart, lungs, liver, musculoskeletal system, central
nervous system
Assessment of renal size, structure and calcification
US and CI
Biopsy occasionally
Assessment of renal function
BUN/creatinine
Concentrating ability
Urinalysis
been described in infants presenting within the first months of life
and progressing to ESRD before the age of two years; this may be
a variant of JN or a distinct genetic entity [132]. The prevalence of
JN is unkifown. Although some reports demonstrate that it
accounts for 10 to 32% of ESRD in children [127], it appears that
in large populations it accounts for 2.4% of childhood ESRD
[133], The autosomal dominant form of medullary cystic disease
seems to be very rare [127].
Diagnosis, clinical manifestations and management consider-
ations. Children with this disease have an early urinary concen-
trating defect leading to polydipsia and polyuria and slowly
progressive renal failure accompanied by growth retardation,
anemia and hypertension in advanced stages. Heavy proteinuria
and hematuria are usually absent. Prominent salt wasting has been
reported in some cases [127, 134]. Diagnosis is difficult because
most findings are nonspecific; ultrasonography shows kidneys of
normal or reduced size, loss of corticomedullary differentiation,
and sometimes medullary cysts; however, usually these are found
only in advanced stages [127]. Abdominal CT was shown in one
case report to be diagnostic, revealing multiple cysts up to 5 mm
in diameter throughout the medulla of both kidneys, whereas US
had been nonspecific [135]. Percutaneous biopsy usually shows a
tubulointerstitial nephropathy with atrophic tubules with seg-
ments of markedly thickened basement membrane as well as
segments of thinned basement membranes [20]; the cysts are often
missed with biopsy.
Extrarenal manifestations have been reported in association
with JN, including congenital hepatic fibrosis [136—141], tape-
toretinal degeneration, mental retardation, cerebellar dysfunction
and skeletal abnormalities [127], but these may represent other
genetic disorders. None of these associations have been found in
the dominant form of medullary cystic disease [1271. Since there
is no specific therapy, management is directed at avoiding and
treating complications of progressive renal insufficiency. Renal
transplantation is the treatment of choice for children with ESRD
due to JN; recurrence has never been observed.
Medullaty sponge kidney
Medullary sponge kidney (MSK) is characterized by nonpro-
gressive dilatation of collecting ducts and tubules, sometimes
associated with multiple small cysts, in one or more renal papillae.
Although autosomal dominant inheritance has been reported in a
minority of cases, the disorder is more often seen sporadically.
The pathogenesis is thought to be due to a developmental
abnormality [142], and other associated developmental and ge-
netic disorders including congenital hemihypertrophy, Ehiers-
Danlos and Marfan's syndrome, Caroli's disease and ADPKD
have been described in patients with MSK [142, 143]. The
diagnosis is made by excretory urography which shows typical
brush-like linear striations or spherical cystic lesions of the renal
papillae; difficulties in diagnosing MSK arise when only one or
two papillae are involved or when the urogram is not of high
quality [142]. The prevalence in unselected patients undergoing
excretory urography is 0.5 to 1% [142, 144]; both sexes appear to
be equally affected.
Although MSK is often asymptomatic, clinical manifestations
can include hematuria, infections and nephrolithiasis. The latter is
a particularly interesting association. The prevalence of MSK
among stone patients has been reported between 12% [144] and
21% [142]. The pathogenetic factors responsible for the associa-
tion with nephrolithiasis and nephrocalcinosis are not entirely
clear. One study found metabolic disorders accounting for the
nephrolithiasis in 93% of stone patients without MSK but in only
60% of stone patients with MSK, concluding that MSKper se is a
cause for nephrolithiasis [144]. In another study the composition
of stones was found to be similar in patients with or without MSK
[145]. Urinary stagnation in the dilated collecting ducts, subtle
acidification defects, hypercalciuria and hyperoxaluria all have
been implicated as contributing to stone formation in patients
with MSK [1421. Some authors have reported an association of
primary hyperparathyroidism with MSK [146], but others view
evidence for a direct association as still insufficient [142].
Management of urolithiasis and nephrocalcinosis in MSK pa-
tients does not differ from that of stone patients of the general
population. ESWL has been used in MSK patients with good
success and without major complications [147, 148]; thiazides
prevent new calcium stone formation in normocalciuric as well as
hypercalciuric patients. If infections and nephrolithiasis are
treated appropriately, MSK does not lead to renal insufficiency.
Acquired renal cystic disease
Several types of renal cysts are acquired. The most common
type is simple renal cysts which are rare in children but increase in
frequency with age. In a recent study unilateral cysts occurred in
1.7% of normal patients 30 to 49 years old, in 11.5% of those 50
to 70 years old and in 22% of those over seventy [149]. Bilateral
cysts were observed in 1, 4, and 9% of these age groups,
respectively [149]. Usually they are asymptomatic and are de-
tected as an incidental finding on an ultrasound study where they
show smooth walls and no intracystic echoes. Occasionally they
can bleed causing flank pain and/or hematuria. CT scanning is
recommended in such cases to exclude malignancy.
Another form of acquired renal cysts is associated with hypo-
kalemia. Patients with primary hyperaldosteronism were found by
CT scanning to have bilateral renal cysts, predominantly in the
medulla, more often than age-matched control patients with
essential hypertension [32]. Moreover, the cysts regressed after
resection of an adrenal adenoma [32]. The pathogenesis is not
clear, but hypokalemia may stimulate tubular cells to proliferate
[150].
The term acquired cystic kidney disease (ACKD) usually refers
to the development of cysts in the kidneys of chronic renal failure
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Table 5. Comparison of various cystic renal disorders
Simple
Feature ADPKD TS VHL ARPKD JN/MCD MSK ACKD cysts
Inheritance AD, '10% new
mutations
AD, 66%
new
mutations
AD, <10% new
mutations
AR AR/AD none none none
Linkage to 16, 4 9, 16 3 6 2 NA NA NA
chromosome gene on
chromosome
16 identified
gene on
chromosome
16 identified
gene identified
Prevalence 1:200-1:1,000 1:10,000 1:36,000 rare rare common up to 90% of
long term
(>10 years)
dialysis
patients
11.5% age
50—70
years
Age of clinical usually adults children and usually adults children, rarely children/ usually children and adults
onset adults young adults adults adults adults
Method of US, linkage US, brain CT US, brain CT or MRI, US, occasionally none IVP CT/US US
diagnosis
Presenting pain, hematuria,
or MRI,
linkage
seizures, renal
linkage
retinal, brain or renal
liver or renal
biopsy
abdominal mass,
reliable
polyuria, renal calculi, hematuria, incidental
symptom infection,
family
screening
bleeding,
cardiac
arrhythmias,
skin lesions,
mental
retardation
tumors,
phaeochromocytoma
HTN, ESRD,
portal HTN
anemia,
ESRD
infection pain,
malignancy,
screening
US
finding
on US
Hypertension 60—75% of
adults
occurs patients with
phaeochromocytoma
common late in
the
course
no dependent on
underlying
disease
no
Gross 42% of adults occurs patients with renal occurs rare common occurs rare
hematuria carcinoma
Nephrolithiasis 20—36% of
adults
no no no no common no no
Renal size normal early,
later enlarged
normal or
enlarged
enlarged if tumorous enlarged reduced normal reduced,
normal or
enlarged
normal
Extrarenal commona common" commonc congenital occur in no no no
manifestations hepatic
fibrosis
JN
Renal rare occurs very common not reported rare no common rare
malignancy
Abbreviations are: AD, autosomal dominant; AR, autosomal recessive; NA, not applicable; US, ultrasound; CT, computed tomography; MRI,
magnetic resonance imaging; IVP, intravenous pyelography; HTN, hypertension; ESRD, end-stage renal disease.
a
e.g. liver cysts, heart valve abnormalities, intracranial aneurysms, diverticula
"skin, brain, heart, retina
retina, brain, phaeochromocytoma
patients with underlying non-cystic renal disorders. Other organs
are not affected.
Epidemiology of ACKD. Acquired renal cysts can be found in 7
to 22% of chronic renal failure patients before the start of dialysis
therapy, but their frequency increases with increasing duration of
dialysis [151]. About 44% of patients treated for less than three
years, 80% of those treated for more than four years and 90% of
those on dialysis for more than 10 years develop ACKD, with
similar incidence for hemodialysis and peritoneal dialysis patients
[151, 152]. Children with long standing renal failure or on
long-term dialysis can also develop ACKD [151—153]. The severity
of ACKD manifests as increasing cyst numbers and renal volumes
with increased duration of dialysis treatment [154]. After success-
ful transplantation ACKD regresses in some but not lI patients.
In one study, 18% of renal allograft recipients had an increase in
cyst numbers in their native kidneys despite long-standing good
transplant function [155], and another study found an increased
prevalence of ACKD among transplant recipients treated with
cyclosporin A [156]. Some but not all studies have demonstrated
an increased frequency of ACKD in males than in females [151,
152, 157]. An overrepresentation of black ESRD patients with
ACKD has been reported [1521.
Diagnosis, clinical manifestations and management consider-
ations. Diagnosis can be made by renal ultrasonography; however,
since the kidneys and cysts are often small, CT scanning may be
more sensitive [152, 154]. Usually ACKD is asymptomatic, but
painful cyst hemorrhage, retroperitoneal hemorrhages, and infec-
tion can occur. Rarely, kidneys with ACKD can enlarge signifi-
cantly, particularly when a previous unilateral nephrectomy has
been performed, and thus mimic ADPKD with symptoms of
heaviness and pain [158], The most serious complication is renal
cell carcinoma (RCC), which is best diagnosed by contrast-
enhanced CT-scanning. Two prospective studies examining the
incidence of RCC have been reported. One from Japan found 2
RCC among 57 patients over a 10 year period [159]; the other
from the USA also found 2 RCC among 30 patients over 7 years
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[154]. Therefore, the annual incidence of RCC in dialysis patients
is about 3 to 6 times greater as compared with an age-matched
general population [160]. The incidence of RCC increases with
duration of dialysis and with increasing severity of ACKD, and
males are 4 to 7 times more often affected than females [151, 152,
1601. In up to 86% of cases RCC are asymptomatic, and therefore
annual screening of dialysis patients by CT has been recom-
mended by some authors [151]. On the other hand, RCC is a
relatively rare cause of death in dialysis patients, and their life
expectancy if often reduced by concomitant, particularly cardio-
vascular, diseases; moreover, often these patients are poor candi-
dates for major surgery if RCC is detected by screening. There-
fore, it has been questioned whether regular screening of all
patients would have a significant impact on patient survival [160].
This needs to be considered in light of the substantial cost.
Probably it is best to screen selected patients who are young, in
general good condition and have risk factors for RCC such as long
duration of dialysis, significant ACKD and large kidneys, partic-
ularly if they are male [160].
Approach to the patient with cystic disease. This array of cystic
disease may seem like a maze, but it is a maze with many clues to
direct the physician to the correct diagnosis in a given patient
(Tables 4 and 5). The family history including autopsy data,
questions about consanguinity and construction of a pedigree are
important first steps; often ultrasonographic information on the
family is needed. This information serves to determine if there is
a familial aspect to the disorder and if transmission is compatible
with autosomal dominant inheritance. Consanguinity increases
the likelihood of a recessive disorder. The patient's age, blood
pressure, renal size and function and the extrarenal manifesta-
tions point the way to the correct diagnosis. Utilizing the infor-
mation supplied in Table 5 one can see which of these manifes-
tations are compatible with the various cystic diseases. Thus, not
all entities would be entertained in a specific patient. For example,
in a patient with a strong family history of cystic renal disease,
ACKD and MSK are not likely to be the disorders, In a patient
with large kidneys, the medullasy cystic diseases and simple cysts
would be excluded; similarly in patients with renal failure simple
cysts, VHL, and medullary sponge kidney would be extremely
unlikely candidates. In contrast, certain entities should always be
considered together. In a child with large kidneys, particularly if
other family members are affected, ADPKD, ARPKD and TS
should all be considered. In some patients diagnosis remains
difficult. For example, the 22 year old patient in an ADPKD
family with a single cyst as her sole abnormality who wishes to
donate her kidney to an affected brother and who has no other
living affected family members cannot be definitively diagnosed as
having ADPKD or a simple cyst. The answers to these dilemmas
await the evolution of the disease and/or the evolution of our
understanding and diagnostic armamentarium.
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